Cargando…
Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021629/ https://www.ncbi.nlm.nih.gov/pubmed/36963011 http://dx.doi.org/10.1371/journal.pgph.0001053 |
_version_ | 1784908539619180544 |
---|---|
author | Raw, Rachael K. Rees, Jon Chadwick, David R. |
author_facet | Raw, Rachael K. Rees, Jon Chadwick, David R. |
author_sort | Raw, Rachael K. |
collection | PubMed |
description | Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal influenza immunisation, in a subset of 492 HCWs. For all doses of BNT162b2/Pfizer vaccine there was a cluster of systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs were no worse in HCWs who received their third/booster dose within 7 days of the influenza jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though younger HCWs experienced more AEs overall. Our findings have implications for vaccine hesitancy and immunisation protocols. |
format | Online Article Text |
id | pubmed-10021629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-100216292023-03-17 Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine Raw, Rachael K. Rees, Jon Chadwick, David R. PLOS Glob Public Health Research Article Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal influenza immunisation, in a subset of 492 HCWs. For all doses of BNT162b2/Pfizer vaccine there was a cluster of systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs were no worse in HCWs who received their third/booster dose within 7 days of the influenza jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though younger HCWs experienced more AEs overall. Our findings have implications for vaccine hesitancy and immunisation protocols. Public Library of Science 2023-02-17 /pmc/articles/PMC10021629/ /pubmed/36963011 http://dx.doi.org/10.1371/journal.pgph.0001053 Text en © 2023 Raw et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Raw, Rachael K. Rees, Jon Chadwick, David R. Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine |
title | Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine |
title_full | Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine |
title_fullStr | Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine |
title_full_unstemmed | Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine |
title_short | Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine |
title_sort | increased adverse events following third dose of bnt162b2/pfizer vaccine in those with previous covid-19, but not with concurrent influenza vaccine |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021629/ https://www.ncbi.nlm.nih.gov/pubmed/36963011 http://dx.doi.org/10.1371/journal.pgph.0001053 |
work_keys_str_mv | AT rawrachaelk increasedadverseeventsfollowingthirddoseofbnt162b2pfizervaccineinthosewithpreviouscovid19butnotwithconcurrentinfluenzavaccine AT reesjon increasedadverseeventsfollowingthirddoseofbnt162b2pfizervaccineinthosewithpreviouscovid19butnotwithconcurrentinfluenzavaccine AT chadwickdavidr increasedadverseeventsfollowingthirddoseofbnt162b2pfizervaccineinthosewithpreviouscovid19butnotwithconcurrentinfluenzavaccine |